Literature DB >> 10597402

Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors.

T Koshiba1, R Hosotani, Y Miyamoto, M Wada, J U Lee, K Fujimoto, S Tsuji, S Nakajima, R Doi, M Imamura.   

Abstract

BACKGROUND: A considerable amount of evidence collected from several experimental systems and clinical studies with nonsteroidal Anti-inflammatory drugs (NSAIDs) indicates that Cox-2 may play a major role in colorectal tumorigenesis, but little information about Cox-2 expression in pancreatic tumors is available. In this study, we investigated Cox-2 expression by means of both immunohistochemical analysis and immunoblot analysis in pancreatic tumors.
METHODS: Fifty invasive ductal adenocarcinomas and 26 intraductal papillary-mucinous tumors (IPMTs) were used for immunohistochemical analysis, and five pancreatic cancer tissues and five pancreatic cancer cell lines for immunoblot analysis.
RESULTS: Cox-2 was expressed in 72% of the invasive ductal adenocarcinomas, 31% of intraductal papillary-mucinous adenocarcinomas, and none of intraductal papillary-mucinous adenomas. The expression rate of Cox-2 in intraductal papillary-mucinous adenocarcinomas was significantly higher than that in intraductal papillary-mucinous adenomas, and that in invasive ductal adenocarcinomas was significantly higher than that in intraductal papillary-mucinous carcinomas. However, there was no significant correlation between Cox-2 expression and the prognosis and clinicopathological factors. Immunoblot analysis identified Cox-2 in all of pancreatic cancer tissues and 60% of cell lines.
CONCLUSION: The biological role of cyclooxygenase-2 (Cox-2) in carcinoma cells should be investigated with reference to the cancer progression of the pancreas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597402     DOI: 10.1007/BF02781733

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  20 in total

1.  Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.

Authors:  R J Coffey; C J Hawkey; L Damstrup; R Graves-Deal; V C Daniel; P J Dempsey; R Chinery; S C Kirkland; R N DuBois; T L Jetton; J D Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Expression of cyclooxygenase-2 in human gastric carcinoma.

Authors:  A Ristimäki; N Honkanen; H Jänkälä; P Sipponen; M Härkönen
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

3.  Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma.

Authors:  T Koshiba; R Hosotani; M Wada; Y Miyamoto; K Fujimoto; J U Lee; R Doi; S Arii; M Imamura
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

4.  Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.

Authors:  B S Reddy; H Maruyama; G Kelloff
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

5.  Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays.

Authors:  C Créminon; A Habib; J Maclouf; P Pradelles; J Grassi; Y Frobert
Journal:  Biochim Biophys Acta       Date:  1995-02-09

6.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

7.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

Authors:  M Tsujii; S Kawano; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 8.  Prostaglandin endoperoxide synthase: why two isoforms?

Authors:  C S Williams; R N DuBois
Journal:  Am J Physiol       Date:  1996-03

9.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

Authors:  S L Kargman; G P O'Neill; P J Vickers; J F Evans; J A Mancini; S Jothy
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

10.  Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.

Authors:  R N DuBois; A Radhika; B S Reddy; A J Entingh
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  20 in total

1.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

2.  Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Authors:  Pamela L Crowell; C Max Schmidt; Michele T Yip-Schneider; Jesse J Savage; Dean A Hertzler; William O Cummings
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.

Authors:  Marketa Hermanova; Petr Karasek; Jiri Tomasek; Jiri Lenz; Jiri Jarkovsky; Petr Dite
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

4.  Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Authors:  Amanda Kirane; Jason E Toombs; Katherine Ostapoff; Juliet G Carbon; Sara Zaknoen; Jordan Braunfeld; Roderich E Schwarz; Francis J Burrows; Rolf A Brekken
Journal:  Clin Cancer Res       Date:  2012-07-24       Impact factor: 12.531

5.  Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Authors:  Daniel Gonnermann; Hans-Heinrich Oberg; Christian Kellner; Matthias Peipp; Susanne Sebens; Dieter Kabelitz; Daniela Wesch
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

6.  5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.

Authors:  René Hennig; Xian-Zhong Ding; Wei-Gang Tong; Matthias B Schneider; Jens Standop; Helmut Friess; Markus W Büchler; Parviz M Pour; Thomas E Adrian
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Authors:  Chantale Charo; Vijaykumar Holla; Thiruvengadam Arumugam; Rosa Hwang; Peiying Yang; Raymond N Dubois; David G Menter; Craig D Logsdon; Vijaya Ramachandran
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

8.  Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density.

Authors:  Hans-U Kasper; Hella Wolf; Uta Drebber; Helmut-K Wolf; Michael-A Kern
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

9.  Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.

Authors:  A Juuti; J Louhimo; S Nordling; A Ristimäki; C Haglund
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

Review 10.  Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?

Authors:  Zhongxing Liao; Kathryn A Mason; Luka Milas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.